ReviewBlood2019
Transfusion-related red blood cell alloantibodies: induction and consequences.
Review in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 1 synthesis or guideline pooled it, 233 citations in OpenAlex.
- Frequency of red blood cell allo-immunization in transfused patients with sickle cell disease in Africa: a systematic review with meta-analysis.African health sciences · 2024Pooled it
- Frequency of red blood cell allo-immunization in patients undergoing blood transfusion at the Uganda Cancer Institute.African health sciences · 2023Trial
- Development and validation of a risk prediction model for postoperative pneumonia in adult patients undergoing Stanford type A acute aortic dissection surgery: a case control study.Journal of cardiothoracic surgery · 2022Trial
- A global survey of blood transfusion practices for patients with sickle cell disease.Transfusion · 2026Article
- Anti-Erythrocyte Antibody Formation in Individuals With and Without Known Sensitisation Pathways Reflecting Indications for Extended Immunohaematology Screening.Journal of clinical laboratory analysis · 2026Article
- Improving In Vitro Antibody Production Using Synthetic Peptide Derived from RhD Loops.Applied biochemistry and biotechnology · 2026Article
- Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.Vox sanguinis · 2026Article
- Global Prevalence and Specificity of Red Blood Cell Antibodies in Blood Donors: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2026Review
- Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease.Antibodies (Basel, Switzerland) · 2026Review
- Patient Blood Management for a Transfusion Dilemma Associated With a Rare Blood Group: A Case Report.Cureus · 2026Article
- Indications for and strategies to reduce blood transfusion for craniosynostosis surgery: a narrative review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
- Cross-sectional survey of the barriers and enablers to preventing iatrogenic anaemia in inpatients with haematological malignancies: The CONSERVE study.Vox sanguinis · 2026Article
- International multicentre evaluation of a new anti-idiotypic anti-daratumumab for resolving pre-transfusion interferences.Vox sanguinis · 2026Article
- The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study.British journal of haematology · 2026Article
- Early Post-Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case-Matched Study.Clinical transplantation · 2026Article
- Blood Cells Far from Equilibrium: Redox Adaptation in Health and Disease.Antioxidants (Basel, Switzerland) · 2026Article
- Clinical applications and methodology updates in HLA typing.BMC immunology · 2026Review
- Targeted protein degradation for fetal hemoglobin induction: a new paradigm in β-hemoglobinopathy therapy.Biomarker research · 2026Review
- Development and validation of a risk prediction model and management strategy for red blood cell irregular antibodies a retrospective cohort study of 521 patients.Clinical and experimental medicine · 2026Article
- Identification of a conformational epitope on the E antigen implicated in anti-E alloimmunization.Blood advances · 2026Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Blood transfusion is the most common procedure completed during a given hospitalization in the United States. Although often life-saving, transfusions are not risk-free. One sequela that occurs in a subset of red blood cell (RBC) transfusion recipients is the development of alloantibodies. It is estimated that only 30% of induced RBC alloantibodies are detected, given alloantibody induction and evanescence patterns, missed opportunities for alloantibody detection, and record fragmentation. Alloantibodies may be clinically significant in future transfusion scenarios, potentially resulting in acute or delayed hemolytic transfusion reactions or in difficulty locating compatible RBC units for future transfusion. Alloantibodies can also be clinically significant in future pregnancies, potentially resulting in hemolytic disease of the fetus and newborn. A better understanding of factors that impact RBC alloantibody formation may allow general or targeted preventative strategies to be developed. Animal and human studies suggest that blood donor, blood product, and transfusion recipient variables potentially influence which transfusion recipients will become alloimmunized, with genetic as well as innate/adaptive immune factors also playing a role. At present, judicious transfusion of RBCs is the primary strategy invoked in alloimmunization prevention. Other mitigation strategies include matching RBC antigens of blood donors to those of transfusion recipients or providing immunomodulatory therapies prior to blood product exposure in select recipients with a history of life-threatening alloimmunization. Multidisciplinary collaborations between providers with expertise in transfusion medicine, hematology, oncology, transplantation, obstetrics, and immunology, among other areas, are needed to better understand RBC alloimmunization and refine preventative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.